- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple sclerosis
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 511KB)
Ofatumumab – March 2024
Ofatumumab: Solution for injection 20 mg in 0.4 mL pre filled pen; Kesimpta®
Last updated
30 May 2025